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Purpose: The goal of this study was to evaluate the imaging features of diabetic mastopathy (DMP) 
and the role of image-guided biopsy in its diagnosis. 
Methods: Two experienced radiologists retrospectively reviewed the mammographic and 
sonographic images of 19 pathologically confirmed DMP patients. The techniques and results of 
the biopsies performed in each patient were also reviewed. 
Results: Mammograms showed negative findings in 78% of the patients. On ultrasonography 
(US), 13 lesions were seen as masses and six as non-mass lesions. The US features of the mass 
lesions were as follows: irregular shape (69%), oval shape (31%), indistinct margin (69%), 
angular margin (15%), microlobulated margin (8%), well-defined margin (8%), heterogeneous 
echogenicity (62%), hypoechoic echogenicity (38%), posterior shadowing (92%), parallel 
orientation (100%), the absence of calcifications (100%), and the absence of vascularity (100%). 
Based on the US findings, 17 lesions (89%) were classified as Breast Imaging Reporting and 
Data System category 4 and two (11%) as category 3. US-guided core biopsy was performed 
in 18 patients, and 10 (56%) were diagnosed with DMP on that basis. An additional vacuum-
assisted biopsy was performed in seven patients and all were diagnosed with DMP. 
Conclusion: The US features of DMP were generally suspicious for malignancy, whereas the 
mammographic findings were often negative or showed only focal asymmetry. Core biopsy is 
an adequate method for initial pathological diagnosis. However, since it yields non-diagnostic 
results in a considerable number of cases, the evaluation of correlations between imaging and 
pathology plays an important role in the diagnostic process. 
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Introduction
Diabetic mastopathy (DMP) is an uncommon benign fibrotic disease of the breast in patients with a 
history of long-standing diabetic mellitus (DM). It was first described as a breast lump consisting of 
fibrous tissue and lymphocytic infiltration in 12 patients with type I DM [1]. Since its first description, 
DMP has been widely recognized as a complication of type I DM. However, some recent reports have 
demonstrated that DMP can also be associated with type II DM [2,3]. One of the earliest studies of 
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DMP reported the imaging findings of DMP in 36 patients with long-
standing type I DM and cataloged some helpful imaging findings, 
such as radiodense glandular tissue, strong acoustic shadowing 
in ultrasonography (US), and firm resistance to needle motion 
during the fine-needle aspiration (FNA) procedure [4]. Subsequent 
studies have reported similar findings, including heterogeneously 
dense breast parenchyma, dense glandular tissue or asymmetry in 
mammograms, and irregular hypoechoic solid lesions with posterior 
acoustic shadowing in US. However, those studies had limited 
generalizability due to the small number of cases available [2,5].
DMP often presents as a palpable mass, but it may also be 
asymptomatic and is sometimes found incidentally during screening 
mammography or US. The imaging features are often suspicious 
for malignancy, meaning that biopsy is necessary. FNA is the least 
invasive option for the diagnosis of breast lesions, but it frequently 
provides inadequate specimens, which is why core needle biopsy 
(CNB) is the preferred method for diagnosing potentially malignant 
breast lesions [4,6,7]. To the best of our knowledge, no research has 
analyzed the imaging findings of DMP based on the Breast Imaging 
Reporting and Data System (BI-RADS), and to our knowledge, no 
studies have evaluated the role of image-guided biopsy in the 
diagnosis of DMP.
Therefore, the purpose of this study was to evaluate the imaging 
features of DMP and the role of image-guided biopsy in its 
diagnosis.
Materials and Methods
This retrospective review of images and medical records was 
approved by the Institutional Review Board of our institution, and 
the requirement for informed patient consent was waived. The 
pathology database of our institution-a tertiary medical center-was 
searched for cases with the keyword ‘diabetic mastopathy’ between 
2004 and 2014. A total of 19 patients who underwent both imaging 
studies and biopsy at our institution were ultimately included in our 
study.
Mammography and US
Bilateral mammograms were obtained using full-field digital 
mammography systems (Selenia, Lorad/Hologic, Danbury, CT, USA; 
Senographe 2000D, GE Medical Systems, Milwaukee, WI, USA), 
except for one patient who underwent mammography before 
2005 using another system (DMR, GE Medical Systems). Standard 
craniocaudal and mediolateral oblique views were routinely 
obtained. Additional mammographic views were obtained as 
needed. Bilateral whole breast US was performed by one of 18 
radiologists with one to 17 years of experience in breast imaging 
with knowledge of each patient’s clinical history and mammographic 
findings. High-resolution US was performed with either 7.5- or 12-
MHz linear array transducers, selected based on their availability (HDI 
5,000 or iU, Philips-Advanced Technology Laboratories, Bothell, WA, 
USA; Logic 9, GE Medical Systems). 
Image-Guided Biopsy 
US-CNB was performed with a 14-gauge automated core needle 
with a 22-mm throw (Stericut with coaxial, TSK Laboratory, Tochigi, 
Japan). At least five core samples were obtained from each lesion. 
US-guided vacuum-assisted biopsy (US-VAB) was performed using 
an 8- or 11-gauge needle (Mammotome, Ethicon Endo-Surgery, 
Cincinnati, OH, USA). 
Analysis of Images and Medical Records
The mammograms and sonograms were retrospectively reviewed by 
two experienced radiologists (J.H.Y. and E.-K.K.) with seven and 18 
years of experience in breast imaging, respectively, who arrived at 
a consensus for each image based on the fifth edition of BI-RADS. 
Only one pathologically confirmed lesion from each patient was 
included in this study. Lesions that did not appear as a mass on US 
were defined as non-mass lesions, although this terminology is not 
used in the fifth edition of BI-RADS. Medical records were reviewed 
to obtain clinical information. The clinical features recorded for 
each patient were the presence of symptoms, the type and duration 
of DM, DM medications, DM complications, and other medical 
history. Items not described in the medical records were marked as 
unknown and excluded from the analysis. Follow-up images and 
medical records were also reviewed to check for any changes of the 
DMP lesions over time. 
Results
Clinical Features
All of the 19 patients were women, ranging in age from 28 to 74 
years (mean age, 55 years). The clinical features of these patients 
are summarized in Table 1. Ten patients (53%) presented with 
palpable masses, while the other nine were asymptomatic. Eleven 
patients (79%) had type II DM, three had type I DM, and five had 
DM of unknown type. The mean duration of DM was 19.5 years 
(range, 4 to 39 years). Eleven patients had DM complications such 
as nephropathy and retinopathy. Other relevant conditions present 
in patients’ medical histories included hypertension (n=11) and 
hypothyroidism (n=3). 
Mammographic and US Features
Mammography was performed in 18 of the 19 patients, with the 
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exception of a 28-year-old patient. All patients presented with 
heterogeneously dense (n=14) or extremely dense (n=4) breasts. 
Only four patients had abnormal findings on mammography, and 
all of the abnormalities involved asymmetry. None of the lesions 
manifested as distortions or suspicious microcalcifications on 
mammography. 
The US findings of DMP are summarized in Table 2. The mean 
size of the lesions measured on US was 22.5 mm (range, 10 to 46 
mm). On US, 13 cases had mass lesions (Fig. 1) while six cases had 
non-mass lesions (Fig. 2). All 13 mass lesions were solid, and their 
common US features were irregular shape (n=9, 69%), indistinct 
margin (n=9, 69%), heterogeneous echogenicity (n=8, 62%), 
posterior acoustic shadowing (n=12, 92%), parallel orientation 
(n=13, 100%), the absence of calcifications (n=13, 100%), and 
the absence of vascularity (n=13, 100%). None of the six non-mass 
lesions had calcifications, but all had posterior shadowing, with two 
being intense. None of the patients had enlarged axillary lymph 
nodes. Multiple similar lesions were seen in nine patients, and seven 
patients had lesions in both breasts. Based on the US findings, 11 
of the 13 mass lesions and all six of the non-mass lesions were 
classified as BI-RADS category 4, with 13 cases classified as 4A, 
three as 4B, and one as 4C. The remaining two were classified as BI-
RADS category 3 (Table 3).
Pathologic Diagnosis and Follow-up
All 19 patients were pathologically diagnosed with DMP. Ten were 
diagnosed via US-CNB, eight via US-VAB, and one through surgical 
excision (Table 3). Among the eight patients who were diagnosed 
with DMP using US-VAB, seven underwent US-CNB before US-
VAB. Initial US-CNB found nonspecific fibrosis in four of these seven 
Table 1. The clinical features of 19 patients with diabetic 
mastopathy
Feature No. (%)a)
Symptom
     Palpable mass 10 (53)
     Asymptomatic 9 (47)
DM type
     Type I 3 (21)
     Type II 11 (79)
     Unknown 5 (
DM complications
     None 2 (15)
     Nephropathy only 4 (31)
     Retinopathy only 4 (31)
     Nephropathy and retinopathy 3 (23)
     Unknown 6 (
DM medications
     Insulin only 6 (40)
     Insulin and oral medication 2 (13)
     Oral medication only 6 (40)
     None 1 (7)
     Unknown 4 (
Other medical history
     Hypertension 11 (61)
     Hypothyroidism 3 (17)
     None 4 (22)
     Unknown 1 (
a)Unknown cases were excluded from the calculation of percentage.
DM, diabetes mellitus.
Table 2. Ultrasonographic features of the 13 patients with 
diabetic mastopathy presenting as a mass lesion
Feature No. (%)
Shape
     Oval 4 (31)
     Irregular 9 (69)
Margin
     Angular 2 (15)
     Indistinct 9 (69)
     Microlobulated 1 (8)
     Spiculated 0 (
     Well-defined 1 (8)
Echogenicity
     Heterogeneous 8 (62)
     Hypoechoic 5 (38)
Posterior shadowing
     Shadowing 7 (54)
     Intense shadowing 5 (38)
     No shadowing 1 (8)
Vascularity
     No 13 (100)
Orientation
     Parallel 13 (100)
Calcifications
     No 13 (100)
BI-RADS category
     3 2 (15)
     4A 9 (69)
     4B 1 (8)
     4B 1 (8)
BI-RADS, Breast Imaging Reporting and Data System.
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Fig. 1. A 64-year-old woman with type II diabetes mellitus 
complaining of a palpable lump in her left upper breast (case 12). 
A. Craniocaudal mammogram shows asymmetry in the left inner 
breast (arrow). LCC, left craniocaudal; RCC, right craniocaudal. 
B, C. Transverse (B) and longitudinal (C) sonograms demonstrate 
an approximately 2.1-cm irregular hypoechoic mass with angular 
margins and posterior shadowing at the area of the palpable lump 
in the left upper inner breast. D. This lesion shows no vascularity. 
Ultrasonography-guided core needle biopsy was performed on 
this lesion, resulting in a diagnosis of diabetic mastopathy. E. 
The histopathologic specimen shows collagenous stroma with 
keloidal features (arrows) and periductal lymphocytic infiltration 
(arrowheads), favoring diabetic mastopathy (H&E, ×100).
A B
C D
RCC LCC
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patients, which was discordant with the imaging findings, leading to 
additional US-VAB. The US-CNB results of the remaining three cases 
were fibroadenoma, usual ductal hyperplasia, and marked sclerosis, 
and all were concordant with the imaging findings. Additional 
vacuum-assisted biopsy (VAB) was performed in one of these three 
cases because the lesion showed an increase in size at follow-up, 
and in the other two cases because the patient requested further 
diagnostic test results. 
Twelve patients were followed up with US for a mean period of 
44.4 months (range, 5.8 to 103.4 months) after the initial biopsy 
(Table 3). During the follow-up period, the lesion became larger in 
two patients, one of whom also developed additional lesions on 
both sides of the breast with similar characteristics to the original 
lesion. Therefore, core biopsies were performed once more on 
the lesion that had grown and on the new lesion, and the results 
confirmed DMP. The lesions disappeared in three of the seven 
patients who underwent VAB, shrunk in two patients, and remained 
the same size in two patients during the follow-up period. None of 
the patients were diagnosed with breast cancer during the follow-
up period. 
Discussion
The etiology and pathophysiology of DMP have not been adequately 
A B
Fig. 2. A 57-year-old woman with type II diabetes mellitus complaining of a palpable lump in her right upper breast (case 10). 
The mammogram showed heterogeneously dense breasts without remarkable findings in the area of the palpable lump (not shown). A, B. 
Transverse (A) and longitudinal (B) sonograms of the area with the palpable lump in the right breast show an ill-defined hypoechoic area 
with posterior shadowing that does not appear as a space-occupying mass. C. The lesion shows no vascularity. Ultrasonography-guided 
core needle biopsy was performed on this lesion. D. The histopathologic specimen shows keloid-like stromal fibrosis (arrows) and periductal 
lymphocytic infiltration (arrowheads) suggestive of diabetic mastopathy (H&E, ×100).
C D
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studies of DMP were far more limited, DMP was thought to be a 
breast disease that specifically occurred in type I DM patients using 
exogenous insulin [15]. However, DMP has also been found in type 
II DM patients. In fact, this study, although there were five patients 
with DM of unknown type, included more type II DM patients (n=11) 
than type I DM patients (n=3). This epidemiological trend may 
reflect the increased prevalence of long-standing type II DM, due to 
its increased incidence and the prolonged survival period of type II 
DM patients. 
The mammographic findings of DMP in our study, which were 
mostly negative findings in dense breast parenchyma, were 
consistent with those reported in previous studies [5,9]. In contrast, 
the US findings of DMP, which are discussed further below, were 
explained, and only hypotheses have been proposed. According 
to one hypothesis, hyperglycemia is the key etiology of DMP. 
Glycosylation is accelerated in hyperglycemia, and excessive levels 
of glycosylated end products induce an autoimmune response, 
causing lymphocytic infiltration and fibrosis. According to this 
theory, the severity and duration of hyperglycemia is an important 
predictive risk factor for DMP [8-13]. Another theory explains DMP 
as breast involvement of systemic autoimmune disease, based on 
the similarity of histological features observed in DMP lesions and 
lymphoepithelial lesions from Hashimoto thyroiditis or Sjögren 
syndrome [14]. Others have proposed that exogenous insulin itself, 
its delivery mechanism, or contaminants therein trigger an immune 
reaction that consequently results in DMP [9,15]. In the past, when 
Table 3. Pathologic diagnosis and follow-up results in 19 patients with diabetic mastopathy
No. Age (yr) Palpability Size (mm)
Lesion 
type
BI-RADS 
category
CNB results
Image-CNB 
correlation
VAB or surgery 
results
Follow-up 
interval 
(mo)
Follow-up results 
1 68 Yes 23 Mass 4A DMP Concordant - - -
2 57 No 14 Mass 4A DMP Concordant - - -
3 66 No 19 Mass 4A DMP Concordant - - -
4 44 Yes 10 Non-mass 4A DMP Concordant - - -
5 49 No 19 Non-mass 3 DMP Concordant - - -
6 51 Yes 21 Mass 4B Usual ductal 
hyperplasia
Concordant DMP - -
7 50 Yes 24 Non-mass 4A Nonspecific 
fibrosis
Discordant DMP (surgery) - -
8 28 Yes 20 Mass 4B DMP Concordant - 61.3 Decreased
9 33 Yes 46 Non-mass 3 DMP Concordant - 12.6 Increased 
10 57 Yes 27 Non-mass 4A DMP Concordant - 12.4 No change
11 74 No 24 Non-mass 4A DMP Concordant - 5.8 No change
12 64 Yes 21 Mass 4A DMP Concordant - 19.9 No change 
New lesions in both 
breasts
13 43 Yes 24 Mass 4A - - DMP 6.1 No change
14 53 Yes 28 Mass 4C Marked 
sclerosis
Concordant DMP 103.4 Decreased
15 59 No 19 Mass 4B Nonspecific 
fibrosis
Discordant DMP 65.6 Disappeared
16 58 No 12 Mass 4A Nonspecific 
fibrosis
Discordant DMP 49.0 Disappeared
New lesion in the 
contralateral breast
17 58 No 24 Mass 4A Fibroadenoma Concordant DMP 78.4 No change
New lesions in both 
breasts
18 73 No 27 Mass 4A Nonspecific 
fibrosis
Discordant DMP 63.0 Disappeared
19 67 No 25 Mass 4A Nonspecific 
fibrosis
Discordant DMP 55.1 New lesion in the 
ipsilateral breast
BI-RADS, Breast Imaging Reporting and Data System; CNB, core needle biopsy; VAB, vacuum-assisted biopsy; DMP, diabetic mastopathy.  
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usually suspicious for malignancy. The presence of conflicting results 
between mammography and US may be helpful in diagnosing DMP.
The US findings varied from case to case, but the most typical 
US findings observed for DMP were an irregularly shaped, 
heterogeneous echoic mass with posterior shadowing, which 
was also consistent with previous studies [5]. These US findings, 
which were observed in the majority of DMP lesions, corresponded 
to a diagnosis of BI-RADS category 4, meaning that the biopsy 
was necessary to exclude malignant tumors from the differential 
diagnosis. 
The US findings in six of the 19 lesions did not resemble masses 
(i.e., were not space-occupying lesions in two different dimensions), 
and we therefore classified them as non-mass lesions. This term 
is not present in the most recent BI-RADS US lexicon, and no 
standardized method exists for interpreting this kind of lesion. In 
clinical practice, however, lesions sometimes cannot be classified 
as masses since they do not meet the definitive criteria of masses. 
Non-mass-like enhancement is a well-known category in the breast 
magnetic resonance imaging lexicon, but this terminology has 
not been commonly used in breast US. However, after the Japan 
Association of Breast and Thyroid Sonology termed these lesions 
non-mass image-forming lesions, the term ‘non-mass’ has started 
to appear in published studies [16,17]. According to a recently 
published report regarding the US and histopathological findings of 
non-mass lesions, five cases of DMP were found among 164 non-
mass lesions [18]. The authors classified the US findings of non-mass 
lesions into four types: type I lesions are non-mass lesions showing 
multiple duct-like structures arranged in a parallel orientation, 
type II lesions involve a mottled area that does not present as a 
discrete mass, type III lesions are non-mass lesions associated with 
architectural distortion, and type IV lesions are non-mass lesions 
presenting with posterior acoustic shadowing. The five DMP lesions 
found in this study all showed a type IV pattern on US, and the 
positive predictive value of type IV non-mass lesions for malignancy 
has been reported to be similar to that of BI-RADS category 4B. All 
of the six non-mass-like DMP lesions found in our study were also 
associated with posterior shadowing, falling into the category of 
type IV lesions. If type IV non-mass lesions can be equated to BI-
RADS category 4B, the pathologic result of DMP from these lesions 
can be considered concordant with the imaging findings. 
Since it is currently impossible to differentiate between DMP and 
breast cancer based on imaging studies, pathological examination 
is necessary in most cases. A sample from the breast lesion can be 
obtained using several methods, and the least invasive procedure 
is usually preferable. However, FNA, which is considered to be the 
least invasive procedure, is not commonly used because it often 
yields inadequate specimens for the diagnosis of DMP [12]. The 
results of our study showed that CNB yielded a conclusive diagnosis 
in approximately half of the cases, as ten of the 18 patients who 
underwent CNB were diagnosed with DMP. Nonspecific fibrosis was 
the most common result among the cases of DMP that were not 
correctly diagnosed by initial CNB. In these cases, as CNB acquires 
only a small part of the lesion, it may have missed the site of 
inflammation, which is an important diagnostic clue for pathologists. 
However, CNB is still a better method for the initial biopsy of 
suspicious breast lesions than FNA or VAB with regard to reliability, 
feasibility, and risk. 
The role of US-VAB in the diagnosis of DMP has not yet been 
studied. In our study, eight patients who did not receive a specific 
diagnosis based on initial CNB findings were pathologically 
diagnosed with DMP via VAB, meaning that surgical excision was 
fortunately avoided. When the initial biopsy of a suspicious lesion 
fails to yield a definitive diagnosis, re-biopsy generally requires a 
larger amount of breast tissue. We suggest that US-VAB is a useful 
method in this situation, as it provides a larger specimen while 
still being less invasive than surgical excision. Surgical excision is 
not required in cases of DMP, as DMP is a universally benign type 
of lesion. Furthermore, previous studies have stated that surgical 
biopsy should not be considered because the recurrence rate of the 
disease has been reported to be as high as 60% [12,19]. 
This study had some limitations. First of all, it was a retrospective 
study, meaning that selection bias was inevitable. Since the study 
population was obtained by searching our institution’s pathology 
database, patients with DMP who did not undergo biopsy, 
presumably due to benign-appearing imaging findings, were missed. 
In addition, since the sonograms were reviewed retrospectively, 
unmeasurable interperformer differences may have been present. 
Many patients had limited clinical information regarding their DM 
status, since their DM was managed in other clinics. Therefore, the 
overall incidence of DMP and its relationship with various clinical 
conditions, such as DM complications, medication, or length of 
hyperglycemia must be evaluated in other future studies with a 
more specific cohort of DM patients. 
In conclusion, while the majority of DMP lesions showed negative 
findings or nonspecific focal asymmetry on mammograms, the US 
features were commonly suspicious for malignancy, corresponding 
to BI-RADS category 4 and making a pathologic diagnosis 
necessary. US-CNB is the method of choice for initial biopsy due to 
its feasibility and reliability. As CNB gives nonspecific results in some 
cases, assessing the correlation between imaging and pathology 
plays an important diagnostic role, and an additional biopsy may be 
required. In the cases included in this study, US-VAB sufficed for a 
conclusive diagnosis, and surgical excision was therefore avoided.
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